Internal Medicine Doctors in North Hills, NY Accepting Medicare
1 Internal Medicine doctors found. Showing 1 - 1
 Lewis M Levin, MD Internal Medicine - Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 40 Windsor Gate Dr, North Hills, NY 11040 Phone: 516-233-2917 Fax: 516-570-6457 |
News Archive
Brazil's ANVISA grants registration for child-adapted formulation of benznidazole for Chagas disease
Today, at the occasion of the 4th DNDi Partners' Meeting in Rio de Janeiro, Brazil, Dr Carlos Gadelha, Secretary of Science, Technology and Strategic Products, Brazilian Ministry of Health, announced that Brazil's National Health Surveillance Agency (ANVISA) granted registration of a new paediatric dosage form of benznidazole, developed through a partnership between the Pernambuco State Pharmaceutical Laboratory (LAFEPE) of Brazil and the Drugs for Neglected Diseases initiative (DNDi).
Leisure-time physical activity might reduce risk of SCD among men with low CRF
Dr Laukkanen said: "Sudden cardiac death (SCD) accounts for approximately 50% of deaths from coronary heart disease. SCD typically occurs shortly after the onset of symptoms, leaving little time for effective medical interventions, and most cases occur outside hospital with few or no early warning signs. Finding ways to identify individuals at elevated risk of SCD would allow early interventions on risk factors to be implemented."
University of Delaware researchers identify prime suspects in cataract formation
When cataracts encroach on the eyes, the only effective remedy is to surgically replace the eyes' lenses with synthetic substitutes. But what if scientists found a way to delay or prevent cataracts from forming in the first place? Researchers at the University of Delaware may have found such an opportunity by identifying the prime suspects in the formation of cataracts - deficiency of two genes that encode regulatory proteins.
AACR rapid and dramatic responses in TRK fusion patients
Loxo Oncology, Inc., a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced new results from its Phase 1 open-label, dose-escalation trial of LOXO-101, a selective inhibitor of tropomyosin receptor kinase (TRK) signaling molecules, and the first preclinical data for its RET and FGFR programs. The data are being presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
› Verified 6 days ago